Rahul Aggarwal
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Rahul Aggarwal sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).
Rahul Aggarwal: 13 sponsored US clinical trials, 3 recruiting.
Rahul Aggarwal sponsors 13 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 13 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Metastatic Malignant Solid Neoplasm, with 3 trials.
Top-decile sponsor footprint
Rahul Aggarwal ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
13 total, page 1 of 1
Imaging of Solid Tumors Using 18F-TRX
NCT06942104
64Cu-GRIP B in Patients With Advanced Malignancies
NCT05888532
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
NCT03682289
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
NCT05011188
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT04471974
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
NCT04926181
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression
NCT04927663
Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies
NCT03590054
Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer
NCT02911467
Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies
NCT02913131
LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC
NCT02494921
Gallium-68 Citrate PET Used in Prostate Cancer
NCT02391025
Phase I Cabazitaxel, Mitoxantrone, and Prednisone Metastatic Castration-Resistant Prostate Cancer
NCT01594918
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 3 |
Therapeutic Areas
What is open in the Rahul Aggarwal pipeline
3 recruiting of 13 indexed (23% open); 4 completed (31%).
Phase mix: 0 late (III/IV) vs 13 early (I/II) (early-phase heavy).
Top condition: Metastatic Malignant Solid Neoplasm (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Rahul Aggarwal: open-pipeline peers nationwide
Peers matched on 13 registered trials and 23% open enrollment, not the therapeutic-area sidebar.
Rahul Aggarwal sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 13 trials (± recruiting share)
- Adaptimmune · 13 trials · 0% recruiting
- Agennix · 13 trials · 0% recruiting
- Akili Interactive Labs · 13 trials · 0% recruiting
- Alumis · 13 trials · 8% recruiting
Sponsors near 23% open enrollment (± trial volume)
- Clemson University · 23% recruiting · 13 trials
- Liberating Technologies · 23% recruiting · 13 trials
- Sequenom · 23% recruiting · 26 trials
- Sumitomo Pharma Switzerland · 23% recruiting · 13 trials
Related
What to do with this Rahul Aggarwal page
13 registered trials is a research-attention snapshot, not an endorsement of Rahul Aggarwal or any single study.
- 3 of Rahul Aggarwal's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Metastatic Malignant Solid Neoplasm is the condition Rahul Aggarwal studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Metastatic Malignant Solid Neoplasm trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Rahul Aggarwal pipeline card: 13 registered trials from official public datasets.Report a data error.